Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma

NCT01209871 ↗

Phase 1 Completed 9 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with lymphoplasmacytic lymphoma. Vaccines made from a person's cancer cells may help the body build an effective immune response to kill cancer cells.

Timeline

Start: 2015-02-26
Primary completion: 2025-04-22
Completion: 2025-04-22

Publications

Thomas SK, Cha SC, Smith DL, Kim KH, Parshottam SR, Rao S, Popescu M, Lee VY, Neelapu SS, Kwak LW. Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol. BMC Cancer. 2018 Feb 13;18(1):187. doi: 10.1186/s12885-018-4094-2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine	Vaccine	—	Other

Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma

Summary

Timeline

Publications

Drugs

Indications